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Myelin forms an insulating sheath surrounding axons in the central and peripheral nervous systems and is essential for rapid
propagation of neuronal action potentials. Demyelination is an acquired disorder in which normally formed myelin degenerates,
exposing axons to the extracellular environment. The result is dysfunction of normal neuron-to-neuron communication and in
many cases, varying degrees of axonal degeneration. Numerous central nervous system demyelinating disorders exist, including
multiple sclerosis. Although demyelination is the major manifestation of most of the demyelinating diseases, recent studies
have clearly documented concomitant axonal loss to varying degrees resulting in long-term disability. Axonal injury may occur
secondarytomyelindamage(outside-inmodel)ormyelindamagemayoccursecondarytoaxonalinjury(inside-outmodel).Viral
induced demyelination models, has provided unique imminent into the cellular mechanisms of myelin destruction. They illustrate
mechanismsofviralpersistence,includinglatentinfections,virusreactivationandviral-inducedtissuedamage.Thesestudieshave
also provided excellent paradigms to study the interactions between the immune system and the central nervous system (CNS). In
this review we will discuss potential cellular and molecular mechanism of central nervous system axonal loss and demyelination in
a viral induced mouse model of multiple sclerosis.
1.Introduction
Demyelination is the process by which axons lose their
normal insulating myelin. Several central nervous system
demyelinating disorders have been described in humans
including multiple sclerosis, neuromyelitis optica (Devic’s
disease), acute disseminated encephalomyelitis, and osmotic
demyelination (central pontine myelinolysis, extrapontine
myelinolysis).
Multiple sclerosis (MS) is a chronic, progressive, or
relapsing and remitting demyelinating disorder that aﬀects
the central nervous system (CNS) speciﬁcally and ranks
as a major cause of nervous system disability in young
adults aged 20 to 45 [1–3]. It has long been hypothesized
that oligodendrocytes (OLGs) and/or the myelin sheath
are the target of immune system-mediated destruction in
MS. Recent studies have demonstrated that axonal damage
[4, 5] also occurs and is likely to be a major component of
long-term disability observed in MS. The etiology of MS
is not very clearly known but the process of demyelination
is believed to involve a Tcell-mediated phenomenon that
may be triggered by one or more viral infections. Clinical
studies show that infectious agents encountered during
adolescence prime the diseases, which appear clinically
later in the adult after a variable period of quiescence
[6, 7]. Despite numerous attempts, a particular responsible
virus has not been identiﬁed. Our research has focused
on understanding the mechanisms of demyelination. We
use the mouse hepatitis virus (MHV) model of murine
demyelination in order to dissect the inﬂammatory and
molecular mechanisms of viral-induced demyelination.
2. InfectiousEtiology of Multiple Sclerosis
The most important evidence that MS might be infectious is
basedonthefactthatthebrainandcerebrospinalﬂuid(CSF)
of more than 90% MS patients contain increased amounts
of IgG, manifest as oligoclonal bands (OGBs) [8]. There
are other but not many CNS disorders in which increased
amounts of IgG and OGBs are found. All those diseases
are inﬂammatory, and most are infectious. Furthermore,
when the speciﬁcity of the increased IgG and OGBs in2 Interdisciplinary Perspectives on Infectious Diseases
those diseases was studied, the IgG in every condition was
shown to be antibody directed against the agent that caused
disease. For example, the oligoclonal IgG found in subacute
sclerosing panencephalitis (SSPE) brain and CSF is directed
against measles virus [9] not herpes simplex virus or mumps
virus; in cryptococcal meningitis, the IgG is directed against
cryptococcus and not another fungus such as candida [10].
These ﬁndings provide a rationale for the notion that the
oligoclonal IgG in MS brain and CSF is antibody directed
against the agent that causes disease.
Moreover, a number of studies have documented viruses
as triggers for MS. The fact that viruses are associated
with multifocal leukoencephalopathy (PML), SSPE, and
postinfectious encephalitis explains the continued interest
i nv i r u s e sa st r i g g e r sf o rM S[ 11, 12]. Studies in herpes
virus have been quite extensive, especially in human herpes
virus 6 (HHV-6) [13–15] and Epstein-Barr virus (EBV)
[16, 17]. Herpes viruses are of particular interest because of
their neurotropic, ubiquitous nature and their tendency to
produce latent, recurrent infections.
However, there are no studies to date that clearly
demonstrate the underlying pathophysiology, correlating the
trigger of viral infection with induction of the demyelination
process. One key to a better insight into the molecular and
cellular mechanisms of MS lies in the development of a reli-
able animal model. Towards this goal several experimental
animalmodelshavebeendevelopedtostudythemechanisms
of virus-induced demyelination.
3. Animal Model for Viral- Induced
DemyelinatingDiseases
Mouse model studies using Theiler’s murine encepha-
lomyelitis virus (TMEV) [18, 19] infection and neurotropic
strains of Mouse hepatitis virus (MHV) infection have
given useful information on putative MS mechanisms [20–
23]. In virus-induced demyelination, infection is a nec-
essary prerequisite for demyelination, and the cause/eﬀect
relationship makes this model an attractive platform for
exploring the etiology and pathogenesis of demyelinating
diseases. Chronic viral-induced dem-yelination is asso-
ciated with viral persistence [24, 25] and concomitant
enhancement of major histocompatibility complex class
I antigens [26–30]. These features parallel many of the
pathologic ﬁndings seen in MS, in contrast to monophasic
viral or postviral human demyelinating diseases such as
acute disseminated encephalomyelitis (ADEM) [31]a n d
PML [32].
4. TMEV- Induced Demyelination Versus
MHV-Induced Demyelination
Infection of susceptible strains of mice with some strains
of TMEV or MHV causes biphasic disease of the CNS,
consisting of early acute disease and late chronic demyeli-
nating disease that appears 30 to 40 days post infection
(p.i) [33]. As early as 30 days p.i, infected mice develop late
chronic demyelinating disease with extensive demyelinating
lesions of the white matter and cell inﬁltrates in the spinal
cord, consisting primarily of CD4+ T cells and CD8+ T
cells, some monocots/macrophages, and a few B cells and
plasma cells. In general, viral infection causes damage to
the nervous system by two mechanisms: direct infection of
neural cells and immune-mediated tissue injury (immuno-
pathology).
Virtually all types of immune response have been
proposed to play important roles in the pathogenesis of
TMEV-induced viral clearance and demyelination. It has
been proposed that demyelination is caused by an immune-
mediated mechanism, in which CD4+ Th1 cells mediate
a delayed type of hypersensitivity response with epitope
spreading [34]. TMEV-induced CD8+ T cells have been
suggested to function as autoreactive cytotoxic cells or
regulatory cells [35]. Antibody against TMEV cross-reacts
with galactocerebroside, and passive transfer of anti-TMEV
antibody can augment demyelination in experimental aller-
gic encephalomyelitis (EAE) [36]. Intracerebral inoculation
with a TMEV-infected macrophage cell line induces acute
focal demyelination [37], and depletion of macrophages
ameliorates TMEV-induced demyelination [38].
Evidence from highly neurovirulent JHM strains of
MHV suggests that MHV-induced demyelination is also
primarily immune mediated [39, 40]. Demyelination can be
completely eliminated in JHM-infected, RAG−/ −mice that
lack functionalTand Bcells,and this process canbe reversed
upon transfer of splenocytes from immunocompetent mice
[41]. Ithas alsobeen shownby depletion and transferstudies
in the JHM model that either CD4+ or CD8+ T cells can
induce demyelination.
However, MHV-A59-induced demyelination has been
shown to develop in the absence of B and T cells [42].
Furthermore, depletion of CD4+ or CD8+ T cells after
the acute stage of infection does not reduce demyelination
[43]. Thus, diﬀerent related strains of MHV may induce
demyelination via unique mechanisms, and it is likely that
in the absence of an intact immune response, some strains
of MHV infection in the CNS are responsible for the onset
of demyelination, possibly through the direct destruction of
OLGs.MHV-induceddemyelination canserve asa model for
oligodendroglial tropic, nonimmune-mediated mechanisms
of demyelination that may have important relevance for our
understanding of MS.
5.MHVPathobiology
MHV is a member of the coronavirus family [44–46]. The
virus infects many vertebrate hosts and induces a variety
of diseases ranging in severity. The outcome and degree
of MHV-induced disease are dependent on several factors,
includingtheageandstrainofthemouse,thestrainofMHV,
and the route of virus inoculation. Even very closely related
strains of MHV diﬀer in pathogenic properties. Some strains
of MHV are purely hepatotropic (e.g., MHV-2) [47]; some
are primarily neurotropic (e.g., JHM, MHV-4, an isolate of
JHM) [22, 48]; while others (e.g., MHV-A59 and MHV3)
[21, 49] are both hepatotropic and neurotropic.Interdisciplinary Perspectives on Infectious Diseases 3
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Figure 1: MHV virion and MHV genome: (a) electron micrographs of coronavirus particle. (b, c) Schematics of structural protein
organization in the MHV virion; MHV virion is somewhat pleomorphic, containing an internal helical RNA genome-nucleocapsid
phosphoprotein (N) complex, surrounded by an envelope containing glycoprotein peplomer (S, E, HE, and M) as speciﬁed in the text.
(d) Organization of the genes in the MHV genome; structural genes are shown in red letters and nonstructural genes in blue letters.
6. MHV Virions
MHV virions are 60–200nm in diameter, somewhat pleo-
morphic (Figure 1(a)), containing an internal helical RNA
genome-nucleocapsid phosphoprotein (N) complex, sur-
rounded by an envelope containing Spike glycoprotein (S),
transmembrane glycoprotein (M), envelope protein (E), and
hemagglutinin-esterase protein (HE) (Figures 1(b) and 1(c))
[50]. Structural proteins expressed at the 3  half of the
MHV genome are believed to be responsible for MHV
pathogenesis. S is a highly glycosylated protein. The outward
radial projection of S gives the virus its family name corona
(like a crown). HE forms smaller spike on virions, but its
function in the virus life cycle is yet not clearly deﬁned. Both
M and E play a role in the assembly of virions [51]. The
virions also have the I protein of unknown function [52].
7. MHV Genome
The MHV genome is a singlestranded, and non-segmented,
polyadenylated RNA, of positive polarity [53]. It is one of the
largest known viral RNA genomes with a length of 31-32Kb
[46, 54, 55]. The RNA genome contains 7 genes, termed
1 to 7, encoding structural as well as nonstructural genes
(Figure 1(d)). There is a leader RNA sequence at the 5  end
of the genome that regulates the transcription of MHV-
RNAs. The next two-thirds of the 5  e n do ft h eg e n o m e
are covered by Gene 1, which encodes a set of polyproteins
withpolymeraseandreplicasefunctions.Gene2encodestwo
proteins including a 30kD product of ORF2a. Gene 2 also
transcribes a 65kD hemagglutinin-esterase protein in some
MHV strains. Genes 3, 6, and 7 code for the spike protein
(S), transmembrane glycoprotein (M), and nucleocapsid
protein(N),respectively.Gene4encodesa12–14kDproduct
while gene 5 encodes a 13kD product of a still unidentiﬁed
nonstructural protein and a membrane-associated E protein.
Italsocontainsalargeopenreadingframeembeddedentirely
in the 5  half of its N gene. This internal gene (I) encodes a
mostly hydrophobic 23kD structural protein [52].
8. MHV Entry andReplication
During lytic infection, MHV enters the host cell via attach-
ment of the S protein to speciﬁc receptors on the host peri-
cellular surface. Carcinoembryonic antigen is one receptor
implicated in infection of cultured mouse cells [56]. The
receptor interaction triggers fusion of the viral and plasma
membranes, allowing entry of the nucleocapsid into the
cytoplasm, where all virus-speciﬁc RNA and proteins are
synthesized. The nascent MHV virions acquire their mem-
brane envelope by implanting themselves into the lumen
of the intermediate compartment between the endoplasmic
reticulum and Golgi complex of the host. Mature virions
are thought to move through the vesicles via the secretory
pathways and exit the cell when the vesicles fuse with the
plasma membrane [57].4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 2: Archetypical histopathology of brain and liver during acute infection with neurotropic strain. MHV-A59: serial coronal sections
from MHV-A59-infected mice at day 5 post infection were stained with H & E or immunostained for CD45 (LCA: leukocyte common
antigen, marker for inﬂammatory cells) or microglia/macrophage marker CD11b (OX42). (a) H & E staining shows acute meningitis and
insetshowsthepresenceofinﬂammatorycellspositiveforLCA.(b)CoronalsectionsstainedforLCAshowacuteencephalitisinbrainsection
characterized by the formation of perivascular cuﬃng in high magniﬁcation. Inset shows presence of inﬂammatory inﬁltrates throughout
the parenchyma. (c) The majority of LCA-positive inﬂammatory cells are stained positive for the macrophage/microglia marker CD11b in
MHV-A59-infected brain parenchyma. (d) Liver pathology from the same infected mouse stained with H & E shows lesions throughout the
liver section.
9. MHV Recombination
Viral recombination has been extremely useful for systemat-
ically exploring the possible biological consequences of viral
genomic diﬀerences. The recombination technique has been
extensively exploited to study reovirus disease in mice, where
the segmented nature of the viral RNA has enabled resorting
of viruses with RNA segments from diﬀerent strains with
diﬀerent biological properties [58]. In sindbis virus and
picornaviruses, a full-length infectious clone of the viral
genome has been exceptionally useful in the study of viral
properties [59, 60].
In MHV, the replicase carries out “discontinuous tran-
scription” in the fusion of body and leader sequences in
subgenomic RNAs and also during recombination events
which occur at high frequency during MHV replication.
High-frequency RNA-RNA genomic recombination events
are archetypal for coronaviruses [61]. These serve as mecha-
nisms of virus evolution and modulation of viral pathogen-
esis, a largely unexplored area of study which oﬀers deep
insight into the genomic control of biological properties.
But for a long time the large genome size was a technical
obstacle to achieving such a goal with coronaviruses. This
problem was circumvented by molecularly cloning defective
interfering-like RNA, leveraging the high RNA recombi-
nation frequencies during mixed infection. This targeted
recombination technique in MHV was developed by Dr.
Paul S. Masters and colleagues and used extensively to
introduce alterations into the 3  end of the MHV genome
[62–64]. It was able not only to exchange speciﬁcally the
structural and non structural genes among the MHV strains
but also to introduce single amino acid substitutions. In
the last few years there have been reports of full-length
infectious clones for many coronaviruses including MHV
and a human coronavirus causing severe acute respiratory
syndrome (SARS) [65–69].
10. MHV Pathogenesis
10.1. Meningoencephalitis, Demyelination, and Axonal Loss.
Upon intracranial (i.c) infection of neurotropic MHVs acute
meningoencephalitis (with or without hepatitis) is the major
pathologic process (Figure 2) .V i r a lt i t e rr e a c h e si t sp e a k
at days 3 and 5 post infection (p.i) [47]. Infectious virus
is cleared within the ﬁrst 10–14 days; however, at this
time mice begin to develop demyelination, either clinical orInterdisciplinary Perspectives on Infectious Diseases 5
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Figure 3: Demyelination and axonal loss in a neurotropic strain of MHV, MHV-A59-infected mouse spinal cord. Serial cross-sections (5μm
thick) from MHV-A59-infected mouse spinal cord at day 7 p.i. were stained for myelin with LFB or by Bielchowsky silver impregnation. (a)
A large demyelinating plaque observed in MHV-A59-infected mouse spinal cord is shown (arrow indicates demyelinated area). (b) In an
adjacent section, the same demyelinating plaque of MHV-A59-infected spinal cord shows loss of axons (arrow indicates area of axonal loss)
(adapted from the work of [73]).
accompanied by chronic hind limb paralysis [21, 70]. Both
MHV-JHM and MHV-A59 cause inﬂammatory demyeli-
nation in the brain and spinal cord (Figure 3(a))w h e r e a s
MHV3 only causes vasculitis [49, 71].
It was formerly believed that in primary MHV-induced
demyelination neuronal axons remain relatively preserved.
Recently, it has been observed that adoptive transfer of
spleen cells from immune MHV B6 mice into MHV-infected
RAG−/ −mice (that are defective in recombinase activating
gene 1 expression, and thus lack mature B or T cells)
resulted in demyelination with increased axonal damage
[72]. They also showed that axonal damage is, in large
part, immune mediated in MHV-infected mice and occurs
concomitantly with demyelination. Concurrent axonal loss
and demyelination have recently also been observed with S
protein recombinant DM strain-infected mouse spinal cord
as shown in Figure 3 ((a) demyelination; (b) axonal Loss)
[73].
10.2. Role of Immune Cells in Viral Clearance and Demyelina-
tion. MHV clearance requires both CD8+ and CD4+ T cells
[74–76]. CD4+ T cells are necessary for proper CD8+ T cell
activation, survival, and retention in the infected CNS [75].
Clearance of infectious virus is mediated by both cytolytic-
and cytokine-mediated mechanisms. Exact mechanisms of
MHV-induced demyelination are unclear although both
macrophages and T cells modulate pathologic changes [41,
77]. Severe combined immunodeﬁcient (SCID) mice, Rag-1
knockout mice, and UV-irradiated mice infected with MHV-
JHM have few lesions 7–15 days p.i despite viral replication
[40, 41, 76–78]. These data suggest that lymphocytes are
required for demyelination. However, demyelination medi-
ated by γδT cells still occurs in nude mice that lack CD4+
and CD8+ T cells [79]. Interestingly, demyelination occurs
to a similar extent in wild type, B cell-deﬁcient, and Rag-1
knockout mice and in mice lacking antibody receptors or
active complement pathways, when infected with MHV-A59
[42].
10.3. Viral RNA Persistence During Chronic Demyelination.
Viral RNA persistenceis essentiallythefailure oftheimmune
system to clear viral RNA from infected organs, mainly
the CNS. Viral RNA persistence has been demonstrated
in infections with all of the neurotropic demyelinating
strains of MHV including JHM and MHV-A59 [24, 25,
80]. Viral RNA persistence appears to be an important
factor and perhaps even a prerequisite for MHV-induced
demyelination during chronic immune-mediated demyeli-
nation. MHV strains that do not persist, such as MHV-2
and Penn 97-1 (laboratory recombinant strains of MHV)
[81, 82], also do not demyelinate. However, the persistence-
positive, demyelination-negative phenotypes of Penn 98-1
and Penn 98-2 (S protein recombinant strain of MHV)
[81] indicate that viral persistence per se is insuﬃcient to
induce demyelination. Penn 98-1 and Penn 98-2 (S protein
recombinant strain) [81] may persist in neuronal cells of
gray matter while demyelinating strains, such as MHV
A59, persist in white matter, suggesting that cell-speciﬁc
persistence is necessary for demyelination. During chronic
infection, MHV RNA persistence in the white matter has
previouslybeendemonstrated[25].However,itisnotknown
which glial cells are mainly responsible for the induction of
demyelination.
10.4. Glial Cell Interaction in the Induction of Demyelination.
A temperature-sensitive demyelinating mutant of JHM is
known to infect mainly nonneuronal cells and speciﬁcally to
have a strong aﬃnity for astrocytes as well as to cause white
matter lesions in the mouse [83, 84]. On the other hand,
neurotropicnondemyelinatingMHV3hasaninvitroaﬃnity
for neurons, ependymal cells and meningothelial cells but
not for astrocytes or oligodendrocytes. MHV3 can induce
an initial ependymitis, meningitis, and encephalitis in the
absence of white matter lesions [49]. These observations
reinforce the importance of glial cell infection in the onset of
demyelination. Astrocytes and microglia play an important
defensive role in MHV pathogenesis by secreting cytokines6 Interdisciplinary Perspectives on Infectious Diseases
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Figure 4: Index of diﬀerential pathogenesis and replication of archetypical neurotropic strain, MHV-A59 and nonneurotropic primarily
hepatotropic strain, MHV-2.
[85–87]. Cytokines are believed to aid in host defense
against MHV by contributing to elimination of the virus
from the CNS. It has been reported that speciﬁc cytokines
and chemokines (such as Interferon α, β,a n dγ), tumor
necrosis factor (TNF-α), IL-2, Il-6, IL-1α,a n dI L - 1 β are all
induced during the acute stage of MHV infection in the
CNS [88]. TNF-α, IL-6, and IL-1β are reportedly secreted by
astrocytes of persistently infected spinal cords [89]. The role
of individual CNS cells in the induction of demyelination
remains to be further elaborated.
11. ComparativeCharacterization of
NaturalandRecombinant Demyelinating
(DM)andNondemyelinating(NDM)Strains
of MHV to Understandthe Mechanisms
of Demyelination and AxonalLoss
Natural and genetically constructed recombinant MHV
strains (generated by targeted RNA recombination) with
diﬀerential pathological properties were used to under-
stand the mechanisms of demyelination and concomitant
axonal loss. These encompass both demyelinating (DM)
and nondemyelinating (NDM) strains of MHVs, on which
we have performed comparative studies correlating the
phenotypes, genomic sequences, and their pathogencity. As
a ﬁrst step mice were inoculated mice with plaque-puriﬁed
demyelinating strain MHV-A59 [21] and nondemyelinating
strain MHV-2 [90]. MHV-A59, a wild type parental strain
of MHV, infects a variety of cell types, including neurons,
astrocytes, oligodendrocytes, microglia, and ependymal cells
[21, 70, 91, 92] in the central nervous system (CNS) and
causes acute meningitis, encephalitis, hepatitis, and chronic
demyelination. In contrast, MHV-2, a closely related fusion
negative [93] strain to MHV-A59, has limited ability to
invade brain and spinal cord, causing meningitis without
encephalitis or demyelination [47, 82] but causing severe
hepatitis (Figure 4), making it an appropriate experimental
negative control for our understanding of mechanisms of
MHV-A59-induced CNS inﬂammatory disease processes.
11.1. Inﬂammation in the Brain. Anti-CD45 (LCA: leukocyte
common antigen) staining conﬁrmed that the increased cells
in the meninges of MHV-A59 (Figure 5(a)) or MHV-2-
infected CNS (Figure 5(b)) consist predominantly of inﬁl-
trating inﬂammatory cells (Figures 5(c) and 5(d)). MHV-
A59 also induced focal acute encephalitis, characterized by
inﬂammatory inﬁltrates in brain parenchyma with perivas-
cular cuﬃng (Figures 5(e) and 5(g)) whereas, MHV-2-
infected brain inﬂammatory cells were restricted to the
meninges, choroid plexus, and subependymal region with
minimal, if any, invasion of brain parenchyma (Figures 5(f)
and 5(h)). The majority of inﬁltrating cells were CD11b+,
a macrophage/microglia marker (Figures 5(i) and 5(j)).
Some CD3-stained inﬁltrating T cells were also found (data
not shown) although nonspeciﬁc background staining of
neurons with available anti-CD3 antibodies made staining
diﬃcult to quantify. Together, data suggests that MHV-
induced CNS inﬂammation consists of mixed inﬂammatory
cells, predominantly macrophages/microglia [73, 94].Interdisciplinary Perspectives on Infectious Diseases 7
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Figure 5: Histopathology of brain sections during acute infection with MHV-A59 compared to MHV-2. 5μm thick serial coronal sections
from MHV-A59- and MHV-2-infected mice at day 5 post inoculation were stained with H & E (a, b) or immunostained for LCA (c–h) or
CD11b (i, j). Histopathology shows acute meningitis characterized by brisk leptomeningeal inﬂammatory inﬁltration in the subarachnoid
space of the basal forebrain in both MHV-A59- (a, c) and MHV-2-infected (b, d) mice. Coronal sections stained for LCA show acute
encephalitis in MHV-A59-infected mouse brain characterized by the presence of inﬂammatory inﬁltrates throughout the parenchyma (e)
and formation of perivascular cuﬃng (g) in high magniﬁcation whereas in MHV-2 infection inﬁltrating inﬂammatory cells were rarely
observed in brain parenchyma (f) and, when present, were restricted to the subependyma (h). The majority of LCA+ inﬂammatory cells
stained positive for the macrophage/microglia marker CD11b in MHV-A59-infected brain parenchyma (i) and the few positive cells in
MHV-2-infected brain (j) remained restricted to subependyma (arrows). Original magniﬁcations for (a–d) and (h) are 100x, for (g, i, and j)
are 200x, and for (e) and (f) are laser-scanned images. (adapted from the work of [94]).8 Interdisciplinary Perspectives on Infectious Diseases
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Figure 6: Comparative histopathology of MHV-A59- and MHV-2-infected mouse spinal cords. Serial cross-sections (5μm thick) from
MHV-A59- and MHV-2-infected mouse spinal cord at day 5 post inoculation were stained with H & E (a, b), LCA (c, d), or LFB (e, f).
Several inﬂammatory lesions (a) with inﬁltrating LCA+ cells (c) were observed in MHV-A59-infected mouse spinal cord (arrows indicate
lesion area) whereas in MHV-2-infected mouse spinal cord no parenchymal lesions were observed (b), with only rare LCA+ inﬁltrates
observed near the central canal (d). An adjacent section of MHV-A59-infected spinal cord shows loss of myelin by LFB staining ((e) arrow
indicatesdemyelinatedarea)whereasnormalmyelinwasobservedinMHV-2-infectedmousespinalcord(f).Originalmagniﬁcationof(a–f)
is 40x. (adapted from the work of [94]).
11.2. Inﬂammation in the Spinal Cord. Pathology was also
assessed in cross-sections of spinal cord from cervical,
thoracic, and lumbar regions. Similar to brain, H & E and
LCAstainingdemonstratedthatbothMHV-A59andMHV-2
inducedmeningitiswhereasonlyMHV-A59inducedmyelitis
(Figures 6(a) and 6(c)). In MHV-2 infection, inﬂammatory
cells were rare and restricted near the ependymal cell lining
of the central canal (Figures 6(b) and 6(d)). Similar to the
brain, the majority of inﬂammatory cells in MHVA59 were
CD11b+ (Figure 6(c)). Luxol fast blue (LFB) staining was
performed to visualize myelin [94]. Demyelinating plaques
developed as early as day 5 post inoculation in MHV-A59-
infected mice (Figure 6(e)), with no demyelination in MHV-
2-infected mice (Figure 6(f)). Day 30-post inoculation tissue
sections from MHV-A59-infected mice showed a similar
pattern of demyelination as on day 5, but the number and
area of plaques were larger, and MHV-2-infected mice did
not exhibit any demyelination. To avoid a high mortality rate
of MHV-2 due to hepatitis, 0.5LD50 doses (50PFUs) were
used.However,toensurethattheinabilityofMHV-2tocause
encephalitis or demyelination is not dose dependent, mice
were also inoculated with MHV-A59 at 50PFUs. MHV-A59
produced larger demyelinating lesions given at 2,000PFUs
than at 50PFUs, but with both doses, 100% of mice were
aﬀected. Results conﬁrm earlier ﬁndings that MHV-A59
induces demyelination whereas MHV-2 is nondemyelinating
at day 30 [47]. Demyelination was not previously assessed
at earlier time points. Demyelination begins as early as
day 5 post inoculation, indicating that MHV-A59-induced
myelin damage begins at the time of acute inﬂamma-
tion, similar to what is observed in MS and EAE lesions
[95].Interdisciplinary Perspectives on Infectious Diseases 9
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Figure 7:OpticnervehistopathologyfromMHV-A59-infectedandMHV-2-infectedmice.Longitudinalsections(5μmthick)ofopticnerve
from MHV-infected mice are shown. Numerous inﬂammatory cells are evident in an MHV-A59-infected optic nerve with ON 5 days post
inoculation stained by H & E (a) and LCA (b). Optic nerve, 5 days post inoculation, with MHV-2 (d) shows a lack of inﬂammation, with
no LCA staining (e) detected. Viral antigen staining of optic nerve from an MHV-A59-infected mouse (c) shows low-level axonal staining
whereas no viral antigen is detected in MHV-2-infected (f) mouse optic nerve. Photographs shown at original magniﬁcation x20. (adapted
from the work of [94]).
11.3. Optic Nerve Inﬂammation. T h ep r e s e n c eo fL C A +
inﬂammation and associated demyelination in brain and
spinal cord led to hypothesize that MHV-A59-infected mice
may develop optic neuritis (ON) similar to experimental ON
in EAE mice. Optic nerves from MHV-A59- and MHV-2-
infected mice were cut into 5μm longitudinal sections and
stained with H & E and inﬂammatory cell markers. For
comparison, relapsing EAE was induced in 8-week-old SJL/J
mice by immunization with proteolipid protein peptide as
described previously in [96]. Mice were sacriﬁced on day
11 post immunization, when incidence of ON peaks and
optic nerves were isolated. Inﬂammatory cells inﬁltrating the
optic nerve sheath and parenchyma are shown by H & E and
LCA staining (Figures 7(a) and 7(b)) 5 days post inoculation
with MHV-A59, similar to inﬂammation seen in EAE ON
[94]. In contrast, optic nerves from MHV-2-infected mice
didnotdevelopON(Figures7(d)and7(e)),withhistological
appearance similar to control optic nerves. Both CD11b+
and fewer CD3+ cells were noted in MHV-A59-infected
optic nerves similar to brain. By day 15 post MHV-A59
infection, optic nerve inﬂammation completely resolved.
Detection of viral antigen in optic nerves was limited to
axonsbecausetherearenoneuronalcellbodiespresent.Light
diﬀuse staining detected in optic nerves from MHV-A59-
infected mice (Figure 7(c)), but not MHV-2-infected mice
(Figure 7(f)), suggests that MHV-A59 viral antigen is likely
present in optic nerve axons. Consistent with the observed
pattern of inﬂammation, optic nerves from MHV-A59-
infected mice had areas of demyelination detected by LFB
staining 30 days post inoculation whereas no demyelination
occurred in MHV-2-infected mice. The degree of optic nerve
inﬂammation was scored on a 0 (no inﬂammation) to 4
(severe inﬂammation) point scale described previously in
[96–98], with any amount of inﬂammation (score 1–4)
considered positive for ON. ON was detected as early as 3
dayspostinoculationwithMHV-A59,withpeakincidenceat
day 5 (Figure 8(a)) and resolution by day 15. At the peak of
ON (day 5), almost 50% (10 of 21) of optic nerves examined
from MHV-A59-infected mice had ON (Figure 8(b)), with
an average relative inﬂammation score of 1.7±0.21 whereas,
only one of 21 nerves from MHV-2-infected mice had even
mild inﬂammation (score 1.0). Incidence of ON in EAE
was 60% (6 of 10) with a 1.83 ± 0.31 average inﬂammation
score, similar to prior studies [96, 98] and comparable to the
incidence induced by MHV-A59 infection.
11.4. Axonal Loss and Demyelination in the Optic Nerve.
To examine whether MHV-A59-induced ON also leads to
axonal loss, optic nerves were stained by Bielschowsky silver
impregnation, and the area of axonal staining was quantiﬁed
as described previously [99]. 30 days post inoculation,
MHV-A59-infected mice had signiﬁcantly decreased axonal
staining compared to control nerves or nerves from MHV-2-
infected mice (Figure 8(c)).10 Interdisciplinary Perspectives on Infectious Diseases
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Figure 8: Occurrences of ON and axonal loss in MHV-infected and EAE mice. (a) ON, determined by presence of any level of inﬂammation
in the optic nerve, is detected as early as day 3 post inoculation with MHV-A59. Incidence increases by day 5, persists at day 7, and resolves
by day 15. In contrast, almost no MHV-2-infected mice develop ON over the same time course. Mean ± SEM incidence from 3 experiments
is shown. (b) The peak incidence of MHV-A59-induced ON, detected at day 5 postinoculation, was 48% (10 of 21 nerves) whereas only one
of 21 nerves from MHV-2-infected mice developed ON. 60% (6 of 10) of optic nerves from EAE (experimental autoimmune encephalitis;
autoimmune model for demyelination) mice develop ON at the peak of inﬂammation on day 11 post immunization. (c) The area of axonal
staining (mean ± SEM) detected by Bielschowsky silver impregnation is signiﬁcantly lower in optic nerves from MHV-A59-infected mice as
compared to optic nerves from control, uninfected mice or MHV-2-infected mice (∗P ≤ .0 5 ) .( a d a p t e df r o mt h ew o r ko f[ 94]).
12. Summary of Comparative Inﬂammatory
Neuropathology of DM (MHV-A59) and
Nondemyelinating (MHV-2) Strainof MHV:
Insight for Understandingthe Mechanisms
of Demyelination and AxonalLoss
Comparative studies demonstrate that MHV-A59, but not
MHV-2, induces demyelination in the CNS during acute
encephalitis, as early as 5 days post inoculation, in addition
to chronic demyelination previously observed at day 30 [47].
Inﬂammation triggered by MHV infection consists of mixed
inﬂammatory cells, predominantly macrophages/microglia,
which diﬀers somewhat from immune-mediated models of
MS where inﬁltrating T cells are signiﬁcant contributors to
pathology [95, 100]. Importantly, MHV-A59 also induces
ON with similar severity and incidence as seen in the
autoimmune antigen-triggered model EAE. Experimental
ON is an important model being used to characterize
neuronal damage and develop novel therapies for MS [98,
101–103], but studies have shown that diﬀerent EAE models,
induced by distinct antigens, lead to diﬀerent mechanisms
of RGC loss [96, 104]. The MHV-A59-induced ON model
willprovideacriticaladjuncttostudythepathophysiologyof
ON secondary to viral-mediated inﬂammation as this is one
mechanism that can cause ON and MS in human patients.Interdisciplinary Perspectives on Infectious Diseases 11
13. Genomic Sequence Comparison between
DM(MHV-A59) andNDM(MHV-2) Strain
ProvidesInsight for Putative Genomic
Control of Neuropathogenic Properties
Sequence comparison between MHV-2 (gene bank accession
number: AF201929) and MHV-A59 (gene bank accession
number 9629812) revealed 94%–98% sequence homology of
the replicase genes, 83%–95% sequence homology of genes
2 a ,3 ,5 b ,6 ,a n d7 ,a n dam a rk e dd i ﬀerence in the sequence of
genes 2b, 4, and 5a among two strains. Among the structural
proteins the S protein interacts with the host receptor
and mediates viral-cell membrane fusion during viral entry
[105]. The ∼1300 amino acid spike protein in MHV-A59 is
usually posttranslationally cleaved into two domains which
associate with each other to form a functional dimer. In the
S protein from MHV-2 strain, however, this cleavage does
not occur, the reasons for which are not clearly evident. A
look at the pairwise alignment between the S proteins from
MHV-A59 and MHV-2 reveals that around 84% residues are
common in both the chains and an additional 10% residue
is similar. The 6% residues with no identity or similarity,
include a 43-residue insertion in MHV-2. This insertion is
by far the most signiﬁcant diﬀerence in the sequence.
The role of S protein as agent of organ tropism and
pathogenesis was hypothesized from comparative studies
of diﬀerent naturally occurring MHV strains [91, 106].
Nucleotide sequencing revealed that alterations in virus
virulence were most closely associated with diﬀerences in
the S gene. These ﬁndings were reinforced using targeted
RNA recombination to exchange speciﬁc gene/genes of
interest between diﬀerent strains of MHV [107–112]. Several
targeted RNA recombination studies have directly demon-
strated that the S gene is a major determinant of virulence of
MHV in mouse brain and liver.
14. Construction of Isogenic Recombinant
Strainsof MHV ExpressingDM and NDM
S trainSP r ot e in
To determine whether the S gene of MHV also contains
determinants of demyelination and whether demyelination
is linked to encephalitis and chronic stage viral persistence,
targeted RNA recombination was used to create new MHV
strains, Penn 98-1 and Penn 98-2, by replacing the S gene
of the encephalitic and DS (MHV-A59) with the S gene of a
closely related, nonencephalitic NDS (MHV-2) [81]. Molec-
ularly cloned vector pMH54 [111, 113], which contains the
entire 3’ end of the genome from MHV-A59, was used
for construction of the recombinant viruses. Comparative
pathological studies between recombinant DS (wtR13) and
the NDS Penn 98-1 and Penn 98-2 demonstrated that Penn
98-1 and Penn 98-2 exhibit similar inﬂammatory inﬁltration
(encephalitis) (Figures 9(a) and 9(b)) in the CNS during the
acute stage. While wtR13 can induce demyelination at day
30 p.i. (Figure 9(c)), Penn 98-1 and Penn 98-2 are unable to
induce demyelination (Figure 9(d)). Penn 98-1 and Penn 98-
2 also exhibited chronic stage persistence in the spinal cord
[81]. For convenience and clarity, in subsequent sections
these recombinant strains were labeled in diﬀerent names
though they are the same but presented in diﬀerent names,
Penn98-1andPenn98-2arereferredtoasRSMHV2(viruses
expressing the MHV-2 spike in the MHV-A59 background)
and wtR13 as RSA59 (viruses expressing the MHV-A59 spike
in the MHV-A59 background).
As alteration of the MHV S protein inﬂuences patho-
genesis, it is important to understand how alteration of
the S protein alters the virus-host interaction. Previously
this type of study was carried out using speciﬁc antibodies
that detect viral antigen in tissues. Targeted recombination
was used to select MHV isolates with stable and eﬃcient
expression of the gene encoding EGFP to facilitate the in
vivo detection of virus in the mouse CNS as well as to
t r a c et h ev i r a le n t r ya n ds p r e a di nt i s s u ec u l t u r e[ 114].
The EGFP gene was inserted into the MHV genome in
place of the nonessential gene 4, as interruption of the
ORF 4 did not decrease neurovirulence in JHM [115]. The
viruses replicated with similar kinetics as wild-type virus
both in tissue culture and in the mouse CNS. They caused
similar encephalitis and demyelination in animals as the
wild-type virus or their recombinant strains; however, they
were somewhat attenuated in virulence. Isogenic EGFP-
expressing viruses diﬀe ro n l yi nt h eSg e n ea n de x p r e s s
either the S gene of the highly neurovirulent. Previously
used names for RSJHMEGFP and RSA59EGFP are S4REGFP and
SA59REGFP, respectively. JHM spike-mediated neurovirulence
was associated with extensive viral spread in the brain
[114]. The diﬀerence in virulence and patterns of spread of
viral antigen between the two isogenic recombinant strains
reﬂected the diﬀerences between parental viruses expressing
each of these S genes [81, 107]. These EGFP-expressing
viruses are powerful tools that can be used to follow viral
spread over time without terminating infection by the ﬁxa-
tion necessary for immunoﬂuorescence. In order to further
compare the diﬀerential pathogenesis and the CNS cell
tropism between DM and NDM strain of MHV, an EGFP-
expressing NDS of MHV RSMHV2EGFP, which contains the
MHV-2 (NDS) S gene in the MHV-A59 background, was
constructed [114]. A cartoon representation of construction
ofEGFP-taggedstrainsofMHVhasbeenshowninFigure 10.
Detailed molecular studies show the EGFP gene is inserted
and expressed at high levels that can be readily detected by
microscopy [114].
15. EGFPExpressingDM andNDM Strain
of MHV: A Tool to Studythe Mechanisms
of MHV-Induced Neuroinﬂammation
Frozen sagittal brain sections were obtained from
RSA59EGFP- and RSMHV2EGFP-infected mice, postﬁxed,
and observed by ﬂuorescent microscopy. One of such
representative EGFP expressing sagittal brain sections has
been shown in Figure 11. EGFP ﬂuorescence was observed
in similar regions of the brain in mice infected with
both the viruses; however, the number of infected cells
diﬀered between strains. Despite the similarity in regional12 Interdisciplinary Perspectives on Infectious Diseases
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Figure 9: Comparative CNS pathology of mice infected with isogenic recombinant strains diﬀers in the S gene. Schematic diagram of
isogenic recombinant strains RSA59 (S gene denoted in green color) and RSMHV2 (S gene demoted in pink color). Encephalitis (a, b).
Haematoxylin- and eosin stained brain sections from the basal fore brain of mice infected with either RSA59 (a) or RSMHV2 (b) at day
5 post infection. Arrows indicate regions of inﬂammation. Demyelination (c, d): spinal cord sections of mice infected with RSA59 (c) or
RSMHV2 (d) at day 30 post infection were stained with Luxol fast blue. The arrows indicate a region of demyelination in (c) and normal
myelinated areas of white matter in (d).
localization, the distribution of RSMHV2EGFP (NDM) strain
is more localized in the brain parenchyma compared to
RSA59EGFP (DM) strain.
15.1. Colocalization of EGFP Positive Cells with Viral Antigen.
To conﬁrm that EGFP positive cells were also positive for
viral antigen, frozen sections were labeled with antinucleo-
capsid antiserum as primary antibody and Texas red goat
antimouse IgG as secondary antibody. EGFP ﬂuorescent
was colocalized with viral antigen in both RSA59EGFP-
RSMHV2EGFP and-infected brain cortical sections (data not
shown). There is a high degree of colocalization of EGFP and
viral antigen in the majority of sections analyzed. Complete
colocalization demonstrated that EGFP ﬂuorescence can
be used to detect viral antigen without performing any
immunostaining.
15.2. Comparative Neuropathology of EGFP Expressing DM
and MDM Strains. Pathology was also assessed in ﬁve to
seven cross-sections of spinal cord from cervical, thoracic,
and lumbar regions at day 7 (peak inﬂammation) and day
30 (peak demyelination) p.i. Demyelinating plaques were
det ect edb yLFBstainsform y elinatda y7p .i.inDM-infect ed
mice (Figure 12(a)) and were quantiﬁed on a 0–3 scale [94]
in four quadrants from two spinal cord levels for each mouse
[116]. Day 30 p.i.-tissue sections from DM-infected miceInterdisciplinary Perspectives on Infectious Diseases 13
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Figure 10: Schematic representation of targeted recombination to construct EGFP-expressing MHVs. The replacement of ORFs 4a and
4b with the EGFP gene was carried out by using recombinant technology, as described previously in [114]. (a) a schematic of the fMHV
genome; it encodes the ectodomain of the feline infectious peritonitis spike in the background of the A59 genome. (b) shows the synthetic
RNA transcribed from the vector pMH54EGFP (MHV-A59 S gene) or pMHV-2EGFP (MHV-2 S gene) [81, 114]. The curved line between
the genome and the pMH54 RNA indicates the region in which the crossover must have occurred. The restriction sites relevant to the
introduction of the EGFP gene are shown. The enlargement of the gene 4 region shows the modiﬁcations in which most of ORFs 4a and 4b
are replaced by the enhanced green ﬂuorescent protein (EGFP) gene. The IGS (intergenic sequence) is the site of initiation of transcription
of mRNA 4. (c) and (d) show the resulting EGFP-expressing viruses: (c) RSA59EGFPexpressing the MHV-A59 S gene and (d) RSMHV2EGFP
expressing the MHV-2 S gene. (adapted from the work of [114]).
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Figure 11: Detection of viral antigen spread by EGFP ﬂuorescence. Mice ware sacriﬁced at day 5 p.i. Brain was removed and processed for
frozen sections. A portion of sagittal brain sections was cut from the middle of the brain of infected mice. Frozen sections were processed for
detection of viral antigen distribution by EGFP ﬂuorescence. Bright EGFP ﬂuorescence was spread throughout the brain section as showed
by montage assembled from 10 serial images (a). Higher magniﬁcation image (b) from the same brain section shows the cellular distribution
of EGFP ﬂuorescence. (adapted from the wprk of [114]).14 Interdisciplinary Perspectives on Infectious Diseases
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Figure 12: CNS pathology of EGFP expressing MHVs. (a, b) Demyelination: luxol fast blue-stained spinal cord sections of mice infected
with RSA59EGFP ( a )o rR S M H V 2 EGFP (b), at day 30 post infection. Thin arrows indicate a region of demyelination, and the arrowheads
indicate normal myelinated area of white matter. (c, d) Encephalitis: microglial nodules: Hematoxylin- and Eosin-stained sections from the
basal forebrain of mice infected with EGFP tagged MHVs at day 7 post infection. Arrows indicate the microglial nodules (microglia with
elongated nuclei) and lymphocytes in the vicinity of neurons in mice infected with RSA59EGFP (c) and RSMHV2EGFP (d). (e, f) Meningitis.
Hematoxylin- and eosin-stained sections from the basal forebrain of mice infected with EGFP tagged MHVs at day 7 post infection:
RSA59EGFP and RSMHV2EGFP. In all cases, there is a brisk leptomeningeal lymphocytic inﬂammatory inﬁltrate. An original magniﬁcation
for (a, b) is 20x and (c–f) is 200x. (adapted from the work of [116]).
showed a similar pattern of demyelination as on day 7, but
the number and area of plaques ware larger [73]. NDM-
infected mice did not exhibit any demyelination either at day
7( Figure 12(b))o ra td a y3 0p . i .( d a t an o ts h o w n )[ 73].
Though comparative histopathological studies demon-
strated that RSA59EGFP could induce demyelination
(Figure 12(a))w h e r e a sR S M H V 2 EGFP cannot induce
demyelination (Figure 12(b)), both RSA59EGFP and
RSMHV2EGFP viruses produced meningoencephalitis (Fig-
ures 12(c)–12(f)). Brain pathology consisted of encephalitis,
characterized by parenchymal lymphocytic inﬁltrates and
microglial nodules with focal neuronophagia (Figures
12(c) and 12(d)). Brain sections from RSA59EGFP showed
comparatively more parenchymal inﬂammation compared
to RSMHV2EGFP. Associated lymphocytic meningitis was
also present in both the strains (Figures 12(e) and 12(f)).
15.3. Signiﬁcant Axonal Loss Occurs Concurrently with
Demyelination Following RSA59EGFP Infection. Though
MHV-induced demyelination is characteristically described
as sparing axons within areas of demyelination, axonal
loss with demyelination in the optic nerve of MHV-A59-
(parental DM) infected mice has been recently observed
[94]. This led to hypothesize that DM MHV may induce
axonal loss in the spinal cord. To examine this, serial sections
of spinal cords from RSA59EGFP- (DM) and RSMHV2EGFP-
(NDM)-infected mice were stained parallaly by LFB and
Bielchowsky silver impregnation. DM-infected spinal cord
sections at both day 7 and day 30 p.i. showed a signiﬁcant
decrease of axonal staining in demyelinating plaque (Figures
13(a) and 13(b)). No demyelination and no axonal loss ware
evident in the NDM-infected mouse spinal cords either at
day 7 (Figures 13(e) and 13(f))o ra td a y3 0p . i .Interdisciplinary Perspectives on Infectious Diseases 15
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Figure 13: Demyelination and axonal loss in DM- and NDM-infected mouse spinal cord. Serial cross-sections (5μm thick) from DM- and
NDM-infectedmousespinalcordatday7p.i.werestainedformyelinwithLFB(a,e)orbyBielchowskysilverimpregnation(b,f)ortoluidine
blue to delineate preservation of myelin, axons, and axon-myelin coherence following DM and NDM infection. (a) A large demyelinating
plaque observed in DM-infected mouse spinal cord is shown (arrow indicates demyelinated area). (b) In an adjacent section, the same
demyelinatingplaqueofDM-infectedspinalcordshowedlossofaxons(arrowindicatesareaofaxonalloss).(e)Normalmyelinwasobserved
in NDM-infected mouse spinal cord. (f) No axonal loss was observed in the NDM-infected mouse spinal cord. Spinal cord sections (1μm
thick) of mice sacriﬁced 30 days p.i. with DM and NDM were stained with toluidine blue (c, d, g, and h). Large demyelinated plaques were
observedinDM-infectedmousespinalcord(C.D).Myelinatedspinalcordwhitematterregionismarked(M),demyelinatedregionofspinal
cord white matter (d), gray matter (g), macrophages (Mφ). In NDM-infected mouse spinal cord, myelin remains relatively preserved with
rareexamplesofearlyaxonaldegenerationcharacterizedbylossofthecentralaxonandcollapseofthemyelinsheath(arrows)(g,h).Original
magniﬁcation for (a, b, e, and f) is 40x. Original magniﬁcation for (c, g) is 100x and fot (d, h) is 1000x. (adapted from the work of [73]).
Tofurtherevaluatethelossand/orpreservationofmyelin
in DM- and NDM-induced inﬂammatory plaques, semithin
spinal cord sections cut at 1-micron intervals from ﬁve
infected mice at day 30 p.i. were stained with toluidine blue.
Control mock-infected mouse spinal cord was used to eval-
uate for background ﬁxation and/or postﬁxation artifacts.
DM-infected spinal cords showed signiﬁcant myelin loss
within plaques (Figure 13(c)). Moreover, high magniﬁcation
images showed inﬁltrating macrophages ﬁlled with myelin
debris (Figure 13(d)). In contrast, in NDM strain RSMHV2-
infected spinal cord sections, myelin is almost completely
preserved, with only rare examples of early axonal degener-
ation, characterized by loss of the central axon and collapse
of the myelin sheath (Figures 13(g) and 13(h)). The presence
of this focal axonal degeneration was not detectable in prior
studies of paraﬃn-embedded tissues by silver impregnation.
15.4. High-Resolution Electron Micrographic Analysis
Conﬁrms Axonal Loss Concurrent with Demyelination
in RSA59EGFP-Infected Mouse Spinal Cord. To further
characterize axonal pathology at the ultrastructural level,
representative foci of demyelination and axonal injury were
selected from toluidine blue-stained sections, and 600 ˚ A
ultrathin sections from Poly-Bed-embedded blocks were
processed for TEM. High-resolution TEM images show a
combination of axonal degeneration and demyelination.
There are extensive axonal loss and many residual empty
vacuoles corresponding to totally degenerated ﬁbers. In
addition, there are numerous hypomyelinated ﬁbers and
naked axons without any myelin sheath, indicative of a
demyelinating process (Figures 14(b)–14(d)). These naked
axons are fully intact with surrounding axolemmas and
axoplasm with preserved microtubules and intermediate
ﬁlaments (Figure 14(e)). In contrast, NDM-infected mouse
spinal cords demonstrate no appreciable axonal loss and
no features of demyelination. Speciﬁcally, there are no
hypomyelinated ﬁbers, no naked axons, no macrophages,
and no evidence of macrophage-mediated myelin stripping.
Instead, there are only rare examples of early axonal
degeneration characterized by loss of the central axon and
collapse of the myelin sheath (Figure 14(f)) as previously
seen in toluidine blue-stained sections. Normal myelinated
region is denoted in Figure 14(a).
15.5. Macrophage-Mediated Myelin Stripping in DM-Infected
Spinal Cord Section. One mechanism of demyelination is
revealed as macrophage-mediated myelin stripping. This
is demonstrated in Figure 15 in which a macrophage is
observed surrounding a myelinated axon. The myelin is
unraveling, yet the axon is completely intact. At the inner16 Interdisciplinary Perspectives on Infectious Diseases
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Figure 14: Electron micrographic analysis of demyelination and axonal loss in DM- and NDM-infected mouse spinal cord. Representative
foci of demyelination and axonal injury were selected from the toluidine blue-stained sections shown in Figure 3 and processed for electron
microscopy. (a) Normal morphology of myelinated axons was exhibited from a non plaque region adjacent to a demyelinated plaque
of DM-infected mouse spinal cord. (b–d) Demyelinating plaque in DM-infected mouse spinal cord showed extensive loss of myelin,
hypomyelination (arrows), complete axonal degeneration with only residual empty vacuoles (arrowheads), naked axons with no myelin
sheath at all (∗), and macrophages (Mφ). (e) A high-magniﬁcation image (120,000x) of a naked axon surrounded only by a single lipid
bilayer shows preservation of cytoskeleton elements (microtubules and intermediate ﬁlaments). (f) In contrast, NDM-infected mouse spinal
cords show only rare examples of early axonal degeneration.  Marks an oligodendrocyte nucleus. Such early axonal degeneration was not
observed in mock-infected mice. Original magniﬁcations: (a) 3000x, (b) 5000x, (c) 6000x, (d) 3000x, (e) 120,000x, and (f) 6000x. (Adapted
from the work of [73]).
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Figure 15: Macrophage-mediated myelin stripping in DM-induced demyelinating plaque. (a) A macrophage (upper portion of the ﬁgure)
is observed surrounding an intact axon (lower portion of the ﬁgure) with uncompacted myelin. Myelin ﬁgures are observed within the
cytoplasm of this macrophage indicative of prior engulfment of myelin. (b) Higher magniﬁcation demonstrates close apposition of the
macrophage cell membrane and an outer layer of uncompacted myelin. The axoplasm and axolemma are intact and the adjacent myelin
shows vesiculation indicative of myelin degeneration. Original magniﬁcation for (a) is 15,000x and for (b) is 40,000x. (adapted from the
work of [73]).Interdisciplinary Perspectives on Infectious Diseases 17
border of the myelin sheath, multiple vacuoles are present
as the entire myelin sheath is lifting oﬀ the axon. The
macrophage cell membrane is in intimate contact with
the outer portion of the myelin sheath as the macrophage
strips away and engulfs the myelin sheath. Multiple vacuoles
with myelin fragments are seen within the cytoplasm of the
macrophage.
15.6. Spinal Cord Inﬂammatory Plaques Contain Predom-
inantly Macrophages. To characterize inﬂammatory cells
within spinal cord plaques, serial sections from DM- and
NDM-infected mice were stained with anti-CD45 (LCA),
anti-CD11b, or anti-CD3. LCA staining conﬁrmed the
presence of inﬁltrating inﬂammatory cells (Figures 16(c)
and 16(d)). Interestingly, the distribution of LCA+ cells was
signiﬁcantly diﬀerent after infection by the two viral strains.
At day 7 p.i., the majority of infected cells in RSA59EGFP-
infected spinal cord were localized to white matter with
only occasional inﬁltration of gray matter (Figures 16(a)
and 16(c)) whereas in RSMHV2EGFP-infected spinal cord,
LCA+ cells were mainly restricted to gray matter (Figures
16(b) and 16(d)). CD11b staining demonstrated that the
majority of LCA+ cells in the spinal cord were CD11b+
(Figures 16(e) and 16(f)). At day 30 p.i., LCA+ c e l l sw e r es t i l l
present in abundance in demyelinating plaques produced
following DM infection (Figures 16(g) and 16(i)), but in
NDM-infected mice, no demyelinating plaques were present
and very few LCA+ cells were retained in the gray matter
(Figures 16(h) and 16(j)). Immunohistochemical data
demonstrate that in DM- and NDM-strain-infected spinal
cord there is an increase of LCA+/CD11b+ cells; however,
the distribution of these inﬂammatory cells is signiﬁcantly
diﬀerent between the two strains.
15.7. DM and NDM Strains Diﬀer in Neuronal Intracel-
lular Distribution of Viral Antigen. To determine whether
diﬀerential localization of viral antigen is responsible for
the observed distribution of inﬂammatory cells, cross-
sections from spinal cord of DM- and NDM-infected mice
were examined. Since the DM and NDM viruses used in
these studies express EGFP, viral distribution was assessed
directly by ﬂuorescence microscopy. On day 7 p.i., the
DM ﬂuorescence was mainly restricted to white matter
(Figures 17(a) and 17(b)) with limited involvement of
gray matter whereas NDM ﬂuorescence was restricted to
gray matter (Figures 17(c) and 17(d)). High-magniﬁcation
ﬂuorescence images in brain from day 7 p.i. demonstrate
numerous neurons and their axons following DM infection
(Figure 17(e)) whereas far fewer ﬂuorescent neurons and
axons are observed following NDM infection (Figure 17(f)).
The ability of DM and NDM to replicate and spread in vitro
wascomparedusingprimaryhippocampalneuronalcultures
and described in very recent studies . Immunostaining of
MAP2b [117] and GFAP [118] demonstrated that cultures
consisted primarily of neurons. At 12 hours intervals,
from 0 to 72 hours p.i., cultures were monitored for viral
a n t i g e ns p r e a db yﬂ u o r e s c e n c em i c r o s c o p y .A t2 4h o u r sp . i .
several infected foci were observed in DM-infected cultures
(Figure 17(g)) whereas, in NDM-infected cultures, very few
discrete cells were positive for EGFP (data not shown). At
72 hours p.i., the average number of EGFP positive cells
was signiﬁcantly increased following infection with DM
(Figure 17(h)). In contrast, NDM-infected cultures had viral
infection restricted only to the initially infected neurons,
with little or no spread to adjacent cells, consistent with in
vivo studies (Figure 17(i)) [73].
To conﬁrm the diﬀerential distribution of viral antigen
in gray and white matter in very recent studies [116]
cross-sections from several regions of all spinal cords
were stained with viral antinucleocapsid antiserum. At day
5 post-infection viral antigens were mainly observed in
the gray matter of the spinal cord in RSA59EGFP-a n d
RSMHV2EGFP- infected mice some viral antigen was also
detected in the white matter. At day 7, most of the viral
antigen in RSA59EGFP was found in white matter whereas
RSMHV2EGFP viral antigen remained mainly restricted to
gray matter with occasional distribution to white matter. In
RSMHV2EGFP- infected mice, viral antigen was occasionally
observed in the white matter, and in some spinal cord sec-
tions of RSMHV2EGFP viral antigen was detected at the gray-
white matter junction as shown in very recent studies [116].
15.8. DM and NDM Strains Exhibit Diﬀerent Cellular
Tropism. The severity of tissue destruction in MHV
infection is mediated by direct viral infection and immune-
mediated destruction. The relative contributions of these
two components diﬀer depending on a number of virus and
host factors including viral tropism, rate of viral spread,
and speciﬁcity of the immune response. During acute
infection, neurotropic and demyelinating strains (DM)
of MHV infect a number of cell types in the CNS such
as neurons, astrocytes, oligodendrocytes, and microglia
[21, 70, 91, 118, 119]. Recently by using the S gene
recombinant virus (S4 R, containing S gene from a highly
neurovirulent MHV-4 on the background of MHV-A59) it
has been demonstrated that S gene-mediated neurovirulence
of MHV is associated with extensive viral spread in the
b r a i ni nb o t hn e u r o n sa n da s t r o c y t e s[ 108]. Thus far it was
not known whether NDM of MHV infects the same cell
types as DS. The phenomenon of demyelination may be due
to primary infection of a single cell type, or alternatively,
infection of diverse CNS cell types leading to the ﬁnal
destruction of OLGs/myelin sheath and the axon.
To compare the cellular tropism of DM and NDM MHV
double-label immunoﬂuorescence on sagittal brain sections
was performed [116]. EGFP ﬂuorescence was used as a viral
antigen marker, MAP2b as a neuron-speciﬁc marker, and
GFAP as an astrocyte-speciﬁc marker. Sections were system-
atically scanned in a blinded fashion. Representative pictures
of dual color ﬂuorescence of viral antigen and MAP2b are
shown in Figure 18. Visual microscopic observations show
that RSJHMEGFP infects and spreads more in neurons in
comparisontotheothertwostrains.InRSJHMEGFP-infected
mice only a very small number of viral antigen positive cells
were also positive for the astrocytic marker GFAP, whereas
in RSA59EGFP-infected mice, EGFP positive cells partially18 Interdisciplinary Perspectives on Infectious Diseases
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Figure 16: Distribution of inﬂammatory cells in the gray matter versus white matter in DM- and NDM-infected mouse spinal cord during
acute infection. Serial cross sections (5μm thick) from DM- and NDM-infected mouse spinal cords at day 7 p.i. were stained with H & E
(a, b), LCA (c, d), or CD11b (e, f). Several inﬂammatory lesions (a) with inﬁltrating LCA+ cells (c) were observed in RSA59EGFP-infected
mouse spinal cord (arrows indicate lesion areas in white matter). The majority of the LCA+ inﬂammatory cells in the inﬂammatory plaques
were positive for the microglia/macrophage marker CD11b (e). CD11b+ cells in DM-infected mice are predominantly in the white matter.
In NDM-infected mice no discrete inﬂammatory lesions were observed (b); however LCA+ cells were observed (d) scattered throughout the
gray matter. These cells were also strongly immunoreactive for CD11b (f). Most of the LCA/CD11b immunoreactive cells were restricted to
gray matter with very little invasion of white matter. Serial cross sections (5μm thick) from DM- or NDM-infected mouse spinal cords at
day 30 p.i. were stained with LFB (g, h) or LCA (i, j). Large demyelinating lesions (g) with inﬁltrating LCA+ cells (i) were observed in DM-
infected mouse spinal cord white matter (arrows indicate lesion area) whereas normal myelin (h) was observed in NDM-infected mouse
spinal cord with only rare scattered LCA+ cells in the gray matter (j). Original magniﬁcation for (a–j) is 40x. (adapted from the work of
[73]).Interdisciplinary Perspectives on Infectious Diseases 19
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Figure 17: DM and NDM diﬀer in their ability to translocate from gray matter to white matter during acute infection. DM- and NDM-
infected mice were sacriﬁced at day 7 p.i.; brain and spinal cord tissues were harvested and processed for frozen sections. Cryostat sections
were post ﬁxed with 95% ice-cold ethanol for 20 minutes and observed by ﬂuorescent microscopy for viral antigen (EGFP ﬂuorescence).
(a) In DM-infected spinal cord, viral antigen positive EGFP-expressing cells are present in both gray and white matters. (b) Area of EGFP
positive cells from (a) is marked in a corresponding LFB-stained section. (c) In NDM-infected mice, EGFP positive cells with viral antigen
are predominantly restricted to the gray matter. (d) Area of EGFP positive cells from (c) is marked in corresponding LFB-stained section.
(e) Axonal distribution of the EGFP ﬂuorescent viral antigen is evident in DM-infected brain. (f) NDM-infected neurons in the brain show
considerably reduced axonal transport of viral antigen. (g–i) to further conﬁrm the ability of DM and NDM to infect neurons and spread
from neuron to neuron, 4-day-old primary hippocampal neuronal cultures were infected with DM and NDM at MOI of 2. Representative
ﬁelds containing an equivalent density of cells are shown in each image. (g) At 24 hours p.i. DM infect a small percentage of the neurons
in culture. (h) By 72 hours p.i. DM-infected neurons were observed to spread from one neuron to the next, as nearly all cells in the culture
containedviralantigendespiteinitialinfectionofonlyasmallpercentageofcells.(i)NDM-infectedneurons,ontheotherhand,demonstrate
limited axonal transport eﬃciency at 72 hours p.i., with only a small number of cells containing a bright concentrated signal that is retained
after primary infection. (adapted from the work of [73]).20 Interdisciplinary Perspectives on Infectious Diseases
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Figure 18: Identiﬁcation of EGFP MHV-infected neurons in the brain at day 5 post infection. Mice were infected intracranially with
RSJHMEGFP, RSA59EGFP, and RSMHV2EGFP. Infected mice were sacriﬁced at day 5 post infection, and the brains were processed, sectioned
and then labeled with anti-MAP2b as primary antiboelies and with Texas red goat anti-mouse IgG as secondary antibodies. EGFP
ﬂuorescence (green) was used to detect viral antigen-positive cells in the basal forebrain. Red ﬂuorescence shows the corresponding labeling
of MAP2b in neurons. Merged images show colocalization of MAP2b and EGFP positive cells. Arrows identify cells double positive for viral
antigen and MAP2b. Bar = 250 microns. (Adapted from the work of [116]).
overlapped with GFAP staining (Figure 19). In addition,
in RSA59EGFP- infected mice EGFP positive cells were not
only astrocytes but also other cell types. In contrast, in
RSMHV2EGFP-infected mice EGFP completely colocalized
with GFAP (Figure 19).
Localization studies showed that MHV strains diﬀer in
their neurovirulence and ability to demyelinate and also
diﬀer in their ability to infect particular CNS cell types.
RSJHMEGFP infects neurons with greater eﬃciency, and
infection may spread more rapidly than in RSA59EGFP,
while RSMHV2EGFP infects neurons with limited eﬃciency.
This is consistent with previous ﬁndings that the degree of
neurovirulence is not only dependent on neuronal tropism
but also on the number of infected neurons and spread
of the infection through neurites [108]. Evidence from
closely related strains of neurotropic viruses including HIV,
TMEV, and reovirus supports the hypothesis that CNS cell
tropism and spread in CNS cells play a major role in the
distribution and type of CNS lesions [120, 121]. Studies with
LCMV and HIV also suggest that virus strains that exhibit
rapidspreadareassociatedwithincreasedimmune-mediated
pathology [122, 123]. Recently, it has been demonstrated
that MHV spread to the spinal cord white matter occurs
very rapidly, and protection from demyelination can be
achieved by inhibiting this viral spread during the acute
phase of infection by recruiting high numbers of MHV-
speciﬁc CD8+ T cells [124]. Nondemyelinating strain is less
able to infect neurons and spread through neurons; on the
other hand, demyelinating strains are highly neuron tropic
and spread rapidly through neurites. In contrast, it has
been observed that a temperature-sensitive demyelinating
mutant of JHM infects mainly nonneuronal cells, havingInterdisciplinary Perspectives on Infectious Diseases 21
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Figure 19: Colocalization of EGFP positive cells with astrocyte marker at day 5 post-infection. Mice were infected intracranially with
RSJHMEGFP, RSA59EGFP and RSMHV2EGFP. Infected mice were sacriﬁced at day 5 post-infection; brains were processed, sectioned and then
immune labeled with anti GFAP (astrocytic marker) antiserum, then stained with Texas red goat anti-mouse IgG as secondary antibodies.
EGFP ﬂuorescence was used to detect viral antigen positive cells; red ﬂuorescence was used to detect GFAP in astrocytes. Merged images
show colocalization of GFAP and EGFP positive cells. Arrows identify cells double positive for viral antigen and GFAP. Bar = 250 microns.
(Adapted from Das [116]).
a strong tropism speciﬁcally for astrocytes and causes
white matter lesions. Similarly, it has been demonstrated
that a monoclonal antibody selected JHM variant, a S
protein mutant, infects the glial cells predominantly in
the CNS, causing subacute demyelination. Interestingly, the
neurotropic and nondemyelinating MHV3 strain, which
has an in vitro tropism for neurons, ependymal cells,
and meningeal cells but not for astrocytes and oligoden-
drocytes, can induce initial ependymitis, meningitis, and
encephalitis in the absence of white matter lesions. Our in
vivo data demonstrate that the highly neurovirulent strain
RSJHMEGFP has very little tropism for astrocytes. RSA59EGFP
andRSMHV2EGFP infectastrocyteswithsimilareﬃciency.As
demyelinatingandnondemyelinatingstrainsproducesimilar
infections in astrocytes, it appears that astrocytic infection
during the acute stage alone may not determine the onset
of demyelination. Our observations suggest that astrocyte
tropism may be a relevant factor in persistent infection but
direct astrocytic infection alone may not be suﬃcient to
induce demyelination. This study highlights the important
role of neural cell tropism of viral antigen in MHV-induced
demyelination in the CNS.
16.Neural Cell-SpeciﬁcViralRNA
Persistence in Induction of
Demyelinationand AxonalLoss
The development of chronic demyelination involves replica-
tion and spread of viral antigen in the spinal cord during the
acute stage of infection and the persistence of viral RNA in
white matter. This is substantiated by current observations
on viral spread of NDM MHV in the spinal cord, where
viral antigen during the acute phase of infection is mainly
restricted to gray matter. In contrast, viral antigen from
demyelinating strains spreads from gray to white matter
duringtheacutestageofinfection[73,116].Speciﬁcally,after
intracranial infection and replication, viral antigens from
the demyelinating strains RSJHMEGFP and RSA59EGFP are
mostly seen in spinal cord gray matter at day 5 post infection
and then in the white matter at day 7 post infection. This
ﬁndingestablishesthatdemyelinatingandnondemyelinating
strains diﬀer in their viral antigen distribution in gray matter
and white matter during acute infection. Viral persistence
observed previously in RSMHV2-infected mouse spinal
cord during the chronic phase of infection may be due22 Interdisciplinary Perspectives on Infectious Diseases
to the presence of viral RNA in gray matter. Viral RNA
for demyelinating strains is known to persist mainly in the
white matter. Due to lack of viral RNA persistence in the
white matter, essential for the induction of demyelination
during chronic infection, RSMHV2 is unable to induce
demyelination. It is possible that cell-speciﬁc viral RNA
persistence is necessary for demyelination. These combined
observations reinforce the importance of glial cell infection
in the onset ofdemyelination.
17.PutativeMechanisticAspect of
DM Strain-InducedDemyelination
andAxonal Loss
Based on experimental evidences it can also be argued
that the spread of viral antigen from neuron to neuron
and from neuron to glial cells plays a critical role in the
induction of chronic stage demyelination. Both DM and
NDM strains infect neurons; however, these strains diﬀer in
their capacity to translocate to white matter as determined
by ﬂuorescence of EGFP tagged viral particles. The current
experiments indicate that axonal transport of viral particles
is an important mechanism mediating not only the extent
of axonal damage but also the subsequent induction of
demyelination in the spinal cord. DM strain shows white
matter involvement early (by day 7 p.i.) and at later time
points that gray matter involvement is essentially absent in
the spinal cord, with only minimal involvement in the brain.
This observation further supports earlier ﬁndings that DM
and NDM strains diﬀer in their viral antigen distribution
during acute infection in the spinal cord [116]. Evaluation
of axonal loss and demyelination in the spinal cord, where
there is clear separation of gray matter and large tracts of
white matter, demonstrated that DM MHV infection begins
in the neuronal cell body and propagates centripetally to the
axon [73] which subsequently induces axonal degeneration
and demyelination. NDM strains were unable to propagate
from gray to white matter and as a result and were unable to
induce demyelination.
The migration and activation of numerous CD11b+
macrophages/microglia to the white matter following viral
spread of DM MHV [73] suggests that recruitment of
these cells mediates demyelination. During DM strain
chronic infection at day 30 p.i., macrophages/microglia
were still present within areas of demyelination whereas
macrophages/microglia and viral antigen were cleared from
the gray matter following NDM strain infection.
One plausible explanation is that MHV spreads intra-
axonally in an anterograde manner within gray matter and
when it reaches the white matter, viral particles are able
to infect oligodendrocytes via direct cell-cell contact. A
less likely possibility is that infection proceeds indirectly
from neurons to oligodendrocytes by intermediary cells such
astrocytes, microglia, or endothelial cells. Regardless of the
mechanism of viral spread, ultimately, macrophages and
microglia are recruited to the areas of infection. In this
way, MHV infection triggers axonal loss and macrophage-
mediated demyelination. However, we have also observed in
NDM strain infection, that axonal degeneration and myelin
disruption can occur in the absence of macrophages. There-
fore, MHV infection can both directly and indirectly cause
axonal loss and demyelination. It may be that the failure
of NDM strain to trigger macrophage-mediated damage is
entirely a function of transport failure to the white matter.
Although there are no experimental data to demonstrate
this, it can be suggested, based on our current neural cell
tropism studies, that neuroinvasion by MHV may require
entry into the nerve endings, transport to the cell body,
replication in the cell body, axonal transport to the synapse,
and transneuronal viral spread. Similar mechanisms of
axonal transport of virus particles have been observed for the
alpha herpesviruses, Herpes simplex virus and pseudorabies
virus [125, 126]. Furthermore, Theiler’s murine encephalitis
virus (TMEV), a nonenveloped virus that, like MHV, causes
chronic demyelination in mice, is able to traﬃc from the
axon into the surrounding myelin in the absence of cell
lysis [127]. Thus, by a mechanism involving transneuronal
spread,MHVmaygainaccesstosynapticallylinkedneuronal
circuits and glial cells. It is not clear, however, which type (s)
of glial cells must be infected in order to promote the devel-
opment of MHV-induced chronic demyelinating disease.
Availablestudiesfocusmainlyonneuronsandastrocytes,
as they represent the majority of infected cells during the
acute stage of MHV infection, but oligodendrocytes cannot
be disregarded. It has been previously demonstrated that
MHV can infect oligodendrocytes [128], but the direct
cytolytic eﬀect of MHV on oligodendrocytes is unclear
[129, 130]. Direct viral infection of oligodendrocytes may
contribute to MHV-induced demyelination, as observed in
another human demyelinating disease, progressive multifo-
cal leukoencephalopathy (PML), which is caused by JC virus
infection of oligodendrocytes [131, 132].
18.PutativeMolecularMechanismsof
Demyelinationand AxonalLoss
The current studies further demonstrate that the molecular
mechanismsunderlyingaxonaldamagearemediatedbytheS
glycoprotein. The recombinant DM and NDM viruses used
are isogenic on a background of the DM MHV-A59 strain
and diﬀer only by the virus-host attachment S glycoprotein.
In vivo, the S protein host receptor is carcinoembryonic
antigen (CEA), which functions as an intercellular adhesion
molecule [56, 133, 134]. However, there is evidence that
other viral entry host factors may also be permissive for
viral infection [135]. Evidently, the diﬀerence in the S
proteins between the DM and NDM strains does not
impair host-receptor interactions or viral entry since both
strains eﬀectively cause encephalitis following transcranial
inoculation. The S protein does, however, appear to play a
critical role in axonal transport, with a lack of viral antigen
spread and subsequent inﬂammation extending into spinal
cord white matter following infection with the NDM strain
in contrast to extensive white matter involvement secondary
to DM strain infection being observed. As mentioned earlier,
MHV S is synthesized as a 180kDa glycosylated precursorInterdisciplinary Perspectives on Infectious Diseases 23
that is posttranslationally cleaved into two 90kDa subunits,
S1 and S2 [136], with a receptor-binding domain in the S1
subunit [137] that is responsible for the initial attachment of
MHV to cell surface receptors. This binding event triggers a
conformationalchangeinSthatallowsS2toinitiatefusionof
thevirusandhostmembranes[138–140].Acandidatefusion
peptidedomainhasbeenidentiﬁedwithinS2[141];however,
the actual fusion peptide for the MHV S has not been
deﬁnitively identiﬁed. MHV-A59 and MHV-2 S proteins
have 82% amino acid sequence identity and 94% similarity,
with the S2 domain relatively more conserved and S1 more
variable [93]. They also diﬀer in their cleavage signal site
whereby MHV-A59 S is cleaved posttranslationally into S1
and S2 subunits, but MHV-2 S protein is not cleaved and
unable to cause fusion in vivo and in vitro. Thus, variable
regions of the S1 domain or diﬀerences in the cleavage signal
site between DM and NDM strains are candidate domains
that may potentially explain the diﬀerential axonal transport
and demyelination observed in our studies and need to be
evaluated further in future studies.
Genes other than the S sometimes referred to as “back-
ground genes” also inﬂuence pathogenesis. In addition to
structural proteins and replicase, all MHVs encode small
unique proteins with unknown functions (ORF2a, 4, and
5a) [142]. The proteins encoded in these three ORFs
appear to be nonessential for replication. It is instructive
to note that, apart from the molecular role of the S gene
in MHV pathogenesis, several additional genes have also
been implicated in the disease etiology. Asides from their
structural roles, N and M proteins are believed to function in
host interactions. In porcine coronavirus, TGEV, mutations
in the M protein ectodomain that impair N-glycosylation
decrease the interferogenic activity and antibodies directed
to the TGEV M ectodomain block IFN-γ induction [143].
For MHV, the glycosylation state of M protein may eﬀect
the ability to induce IFNγ and also to replicate in the liver
[144]. In measles infection, a defective M transmembrane
protein has been related to the diﬀerence in the ability of
the virus to persist in the CNS and cause subacute sclerosing
panencephalitis (SSPE) [145]. The N protein has been impli-
cated in MHV-induced hepatitis [146, 147]. In addition,
the replicase and other non structural proteins could aﬀect
tropism and pathogenesis by inﬂuencing the rate of viral
replication perhaps by interactions with cell type speciﬁc
factors or with elements of the immune response [148].
19. Conclusion
Current available studies demonstrate that the mechanisms
of white matter injury in this model of CNS demyeli-
nating disease are due to a combination of both axonal
injury/loss and myelin damage. In DM infection, there is
concomitant axonal loss and demyelination, and at least
some demyelination is due to macrophage-mediated myelin
stripping. One can hypothesize that axonal degeneration
follows in this immune-mediated pathogenesis. Partial
axonal loss also appears to occur secondary to direct
viral-induced cytopathic eﬀects, a non-immune-mediated
mechanism. Following NDM infection, although relatively
rare, myelinated ﬁbers in the spinal cord white matter
exhibit early axonal degeneration in the absence of any
associated inﬂammation. Therefore, MHV infection exhibits
diverse mechanisms of axonal loss and demyelination that
are both immune and nonimmune mediated. While the
underlying mechanisms leading to the development of MS
in patients are not known, numerous studies have provided
evidence to suggest that a viral infection may trigger this
autoimmune demyelinating disease. The critical role of the
S glycoprotein in viral transport and subsequent axonal
and myelin damage demonstrated in the current studies
suggests that targeted disruption of the S glycoprotein-
host interaction has the potential to prevent the onset or
progression of demyelination. Future experiments need to
be geared toward identifying how the S proteins interact
with the axonal transport system. Clues may be provided
by other human viral neurologic infections, including those
caused by such diverse viruses as Herpes Simplex and Rabies,
as they take advantage of the axonal transport system in
order to maximize spread and neurovirulence. Experimental
mouse model provides an excellent means by which the
particular host-virus interactions responsible for successful
axonal transport can be dissected and clariﬁed.
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